NO20080552L - GLP-1 farmasoytiske sammensetninger - Google Patents

GLP-1 farmasoytiske sammensetninger

Info

Publication number
NO20080552L
NO20080552L NO20080552A NO20080552A NO20080552L NO 20080552 L NO20080552 L NO 20080552L NO 20080552 A NO20080552 A NO 20080552A NO 20080552 A NO20080552 A NO 20080552A NO 20080552 L NO20080552 L NO 20080552L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
glp
analogues
peptide
glucagon
Prior art date
Application number
NO20080552A
Other languages
English (en)
Inventor
Zheng Xin Dong
Roland Cherif-Cheikh
Frederic Lacombe
Jose-Antonio Cordero Rigol
Resurreccion Alloza Miravete
Maria Dolores Tobalina Maestre
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20080552L publication Critical patent/NO20080552L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår peptidanaloger av glukagonlignende peptid-1, de farmasøytisk akseptable saltene derav, fremgangsmåter for anvendelse av slike analoger for behandling av pattedyr og farmasøytiske sammensetninger anvendelige derfor omfattende nevnte analoger.
NO20080552A 2005-06-30 2008-01-30 GLP-1 farmasoytiske sammensetninger NO20080552L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69614205P 2005-06-30 2005-06-30
PCT/US2006/025826 WO2007005738A2 (en) 2005-06-30 2006-06-30 Glp-1 pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20080552L true NO20080552L (no) 2008-03-27

Family

ID=37605098

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080552A NO20080552L (no) 2005-06-30 2008-01-30 GLP-1 farmasoytiske sammensetninger

Country Status (13)

Country Link
US (2) US8236759B2 (no)
EP (2) EP1904525A4 (no)
KR (1) KR20080028981A (no)
CN (1) CN101258163B (no)
AR (1) AR055346A1 (no)
AU (1) AU2006265814B2 (no)
CA (1) CA2617859A1 (no)
EA (1) EA012287B1 (no)
MX (1) MX2008001468A (no)
NO (1) NO20080552L (no)
NZ (1) NZ565535A (no)
TW (1) TWI364292B (no)
WO (1) WO2007005738A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523473A (ja) * 2006-12-29 2010-07-15 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ｇｌｐ−１医薬組成物
US8981094B2 (en) * 2007-06-08 2015-03-17 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
EP2152269B1 (en) * 2007-06-08 2014-04-23 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
EP2216042A1 (en) * 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
EP3139948B1 (en) * 2014-05-07 2020-03-04 Novo Nordisk A/S Treatment of diabetes type 1 using glp-1 and anti-il-21

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591496A (en) * 1984-01-16 1986-05-27 Massachusetts Institute Of Technology Process for making systems for the controlled release of macromolecules
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CA2143044C (en) * 1994-02-21 2005-04-12 Yasutaka Igari Matrix for sustained-release preparation
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1529534B1 (en) 1996-11-12 2007-07-11 Novo Nordisk A/S Use of GLP-1 peptides
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DK1061948T3 (da) * 1998-03-20 2003-03-31 Takeda Chemical Industries Ltd Præparat til vedvarende frigivelse af et fysiologisk aktivt polypeptid samt fremstilling deraf
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
JP2002523333A (ja) 1998-07-31 2002-07-30 ノボ ノルディスク アクティーゼルスカブ Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CZ295044B6 (cs) * 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
JP4548623B2 (ja) * 1999-02-24 2010-09-22 多木化学株式会社 生体材料
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
DE60105547T3 (de) 2000-01-10 2014-12-31 Amylin Pharmaceuticals, Llc Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001228327A1 (en) 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
WO2001068112A2 (en) 2000-03-14 2001-09-20 Goeke Burkhard Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
AU6323001A (en) 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
ATE424413T1 (de) * 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US20020115605A1 (en) 2000-08-24 2002-08-22 Matthew During Novel peptide with effects on cerebral health
DE60142351D1 (de) 2000-10-20 2010-07-22 Amylin Pharmaceuticals Inc Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid
WO2002048192A2 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
CN1501809B (zh) 2000-12-13 2012-10-10 伊莱利利公司 应用胰高血糖素样促胰岛肽的长期治疗方案
PL373846A1 (en) 2001-10-01 2005-09-19 Eli Lilly And Company Method of reducing mortality and morbidity associated with critical illnesses
US20050053588A1 (en) 2001-10-18 2005-03-10 Li Yin Conversion of liver stem and progenitor cells to pancreatic functional cells
JP2005508360A (ja) 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１およびインスリンの二相混合物
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
EP1694278A4 (en) 2003-12-16 2009-08-12 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
ES2375802T3 (es) * 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
ES2400687T3 (es) * 2004-04-23 2013-04-11 Amgen Inc. Formulaciones de liberación sostenida
EP1758597B1 (en) * 2004-05-20 2012-09-12 Diamedica Inc. Use of drug combinations for treating insulin resistance

Also Published As

Publication number Publication date
AR055346A1 (es) 2007-08-22
NZ565535A (en) 2011-03-31
AU2006265814A1 (en) 2007-01-11
US8236759B2 (en) 2012-08-07
US20120277151A1 (en) 2012-11-01
CA2617859A1 (en) 2007-01-11
EP1904525A4 (en) 2009-10-21
EP1904525A2 (en) 2008-04-02
TW200740456A (en) 2007-11-01
CN101258163B (zh) 2013-08-21
EA012287B1 (ru) 2009-08-28
TWI364292B (en) 2012-05-21
EP2441460A1 (en) 2012-04-18
WO2007005738A2 (en) 2007-01-11
EA200800181A1 (ru) 2008-06-30
AU2006265814B2 (en) 2012-05-10
CN101258163A (zh) 2008-09-03
MX2008001468A (es) 2008-04-07
KR20080028981A (ko) 2008-04-02
US20070021339A1 (en) 2007-01-25
WO2007005738A3 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
NO20100307L (no) GLP-1 analoger
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
UA114710C2 (uk) Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить
EA201000399A1 (ru) Композиции и способы использования проостровковых пептидов и их аналогов
UA95975C2 (ru) N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
WO2005058252A3 (en) Glp-1 pharmaceutical compositions
EA200802058A1 (ru) Производные циклоалкиламинокислот и их фармацевтические композиции
ATE522226T1 (de) Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms
HK1088840A1 (en) Stable analogs of glp-1 glp-1
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2004074315A3 (en) Analogues of glp-1
NO20053111L (no) Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EA200900373A1 (ru) Реконструированные сурфактанты, обладающие улучшенными свойствами
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CY1119819T1 (el) Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application